Bristol-Myers Squibb Company (BMY)
| Market Cap | 81.59B |
| Revenue (ttm) | 45.53B |
| Net Income (ttm) | -6.15B |
| Shares Out | 2.03B |
| EPS (ttm) | -3.10 |
| PE Ratio | n/a |
| Forward PE | 5.71 |
| Dividend | $2.40 (5.96%) |
| Ex-Dividend Date | Apr 4, 2024 |
| Volume | 13,494,145 |
| Open | 40.28 |
| Previous Close | 40.49 |
| Day's Range | 39.94 - 40.70 |
| 52-Week Range | 39.94 - 66.46 |
| Beta | 0.44 |
| Analysts | Hold |
| Price Target | 59.56 (+47.98%) |
| Earnings Date | Apr 25, 2024 |
About BMY
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BMY's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for BMY stock is "Hold." The 12-month stock price forecast is $59.56, which is an increase of 47.98% from the latest price.
News
Bristol Myers Squibb Shares Cross 6% Yield Mark
In trading on Wednesday, shares of Bristol Myers Squibb were yielding above the 6% mark based on its quarterly dividend (annualized to $2.4), with the stock changing hands as low as $39.94 on the day....
2024 is being called ‘the year of the dividend.' These 5 stocks keep on giving.
Declining U.S. interest rates will boost yield-paying shares.
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Lin...
Menten AI Announces Completion of Research Collaboration with Bristol Myers Squibb
SAN FRANCISCO--(BUSINESS WIRE)-- #CADD--Menten AI, Inc., a biotechnology company with a generative AI platform for design and optimization of peptide macrocycles, today announced the completion of a p...
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications.
This up-and-coming cancer treatment could be a $25 billion market opportunity — it's already a hotbed for M&A
Targeted radiopharmaceuticals has caught the eye of big pharma. The therapy delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule.
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EMERGENT--Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting.
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million
A judge in Hawaii on Tuesday ordered Bristol Myers Squibb and Sanofi to pay more than $916 million to the state for failing to warn non-white patients of health risks from its blood thinner Plavix, up...
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries.
NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
Additional funding will be used to explore novel biology around the MMR pathway and accelerate progression of the lead program into candidate selection LONDON , May 22, 2024 /PRNewswire/ -- NeoPhore L...
3 Cheap and Dependable Dividend-Growth Stocks to Buy
These dividend growers look undervalued today.
Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #MentalHealthMonth--Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Cam...
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivo and hyaluronidase).
Trade Tracker: Goldman Sachs, Bristol Myers and TJX
The Investment Committee shares their latest portfolio moves.
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #EADV--New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis.
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Breyanzi--Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma...
US FDA approves expanded use of Bristol's cancer cell therapy
The U.S. Food and Drug Administration on Wednesday approved the expanded use of Bristol Myers Squibb's cancer cell therapy Breyanzi to include the treatment of adults with a type of blood cancer that ...
Bristol-Myers Squibb dragged down the S&P 500 this earnings season
More than 90% of the companies in the S&P 500 (^GSPC) have reported their earnings for the first quarter of 2024, which yielded a mostly strong result for the index. However, Bristol-Myers Squibb (BMY...
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #NSCLC--Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial.
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Participate in Upcoming Investor Conferences.
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CRC--European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BLA--U.S. Food and Drug Administration Accepts Bristol Myers Squibb's Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase).
Should You Pick Bristol Myers Squibb Stock At $45?
Bristol Myers Squibb Bristol Myers Squibb (NYSE: BMY) recently reported its Q1 results, with revenues and earnings above the street estimates. The company reported revenue of $11.9 billion and an adju...
Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb
AMSTERDAM--(BUSINESS WIRE)--Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, today announced that it has entered into a research collaboration with Bristol My...
Judge rejects J&J, Bristol Myers Squibb challenges to Medicare drug price negotiations
The decision is another win for the Biden administration in a bitter legal fight with several drugmakers over the constitutionality of the price talks.